Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]

Continue reading »


Treatment of Multisystem Inflammatory Syndrome in Children McArdle. NEJM 2021; 385: 35-45.DOI: 10.1056/NEJMoa2102968 Clinical Question In children with multisystem inflammatory syndrome, what affect do different treatments have on the composite of inotropic support or mechanical ventilation by day 2 or death, and disease severity by day 2? Background Multisystem inflammatory syndrome in children (MIS-C) is a new, rare but serious […]

Continue reading »
1 2 3